The impact of implementing current treatment modalities and female sex on gastric cancer outcomes, 2000–2016: a longitudinal nationwide cohort study

Authors

  • Panu Aaltonen a Department of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Harri Mustonen a Department of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Katriina Peltola b Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Olli Carpén c Medicum, Research Program in Systems Oncology and HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Pauli Puolakkainen a Department of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Caj Haglund a Department of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Malin Sund a Department of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Hanna Seppänen a Department of Surgery, Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

DOI:

https://doi.org/10.1080/0284186X.2023.2259081

Keywords:

Gastric cancer, epidemiology, survival

Abstract

Background

The implementation of current treatment modalities and their impact on nationwide gastric cancer outcomes remain poorly understood. Biological differences between females and males could impact survival. We aimed to analyze rates of gastric surgery, chemotherapy, and radiotherapy as well as changes in overall survival among gastric cancer patients diagnosed between 2000–2008 and 2009–2016, respectively, in Finland.

Material and methods

Data on gastric cancer patients were collected from national registries. Cox regression analysis and the Kaplan–Meier method were used to analyze differences in survival.

Results

We identified 9223 histologically confirmed gastric cancer patients. The rate of gastric surgery decreased from 44% (n = 2282) to 34% (n = 1368; p < 0.001). The proportion of gastric surgery patients who underwent preoperative oncological treatment increased from 0.5% (n = 12) to 16.2% (n = 222) between the calendar periods (p < 0.001) and stood at 30% in 2016. The median overall survival (OS) improved from 30 months [95% confidence interval (CI) 28–33] to 38 months (95%CI 33–42; p = 0.006) and the period 2009–2016 independently associated with a lower risk of death [hazard ratio (HR) 0.78, 95%CI 0.70–0.87] among patients who underwent gastric surgery. Females exhibited a lower risk of death (HR 0.88, 95%CI 0.81–0.97) among patients who underwent gastric surgery.

Conclusion

Preoperative oncological treatment was gradually introduced into clinical practice and OS among gastric surgery patients improved. Moreover, female surgical patients exhibited a better survival than male patients.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2023-12-02

How to Cite

Aaltonen, P., Mustonen, H., Peltola, K., Carpén, O., Puolakkainen, P., Haglund, C., … Seppänen, H. (2023). The impact of implementing current treatment modalities and female sex on gastric cancer outcomes, 2000–2016: a longitudinal nationwide cohort study. Acta Oncologica, 62(12), 1732–1741. https://doi.org/10.1080/0284186X.2023.2259081